drugset
drugset / Trial / NCT02225574

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

NCT02225574 ↗

Phase 1 Terminated 1 enrolled M.D. Anderson Cancer Center Array BioPharma · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerated dose of the combination of nilotinib and MEK-162 that can be given to patients with CML or acute leukemia. Researchers also want to learn if the drug combination can help to control the disease. The safety of the drug combination will also be studied.

Timeline

Start
2015-03-11
Primary completion
2017-02-02
Completion
2017-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 30 mg Oral
Subject Nilotinib Small molecule 400 mg Oral

Indications

leukemia